|Conatus Pharmaceuticals Inc.|
16745 West Bernardo Drive
United States - Map
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
|Dr. Steven J. Mento Ph.D.,
Co-Founder, Chief Exec. Officer, Pres and Director
|Dr. Alfred P. Spada Ph.D.,
Co-Founder, Chief Scientific Officer and Exec. VP of R&D
|Dr. David T. Hagerty M.D.,
Exec. VP of Clinical Devel.
|Mr. Charles J. Cashion MBA,
Co-Founder, Chief Financial Officer, Sr. VP of Fin. and Sec.
|Mr. Daniel L. Ripley MBA,
VP of Bus. Devel. & Program Management
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|